Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis, Long-Acting Injections | E51

<p>Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breathe new life into generic drugs, making it easier for patients to stick to their treatment regimen. This has applications in many diseases, including hormonal disorders and obesity, with new formulations of GLP-1 agonists.He also discusses how long-acting versions of buprenorphine can help patients to overcome opioid addiction and tackle the global opioid crisis.</p><p>---</p><p>Learn how YSDS helps move your most sensitive life sciences shipments worldwide, safely, on time, with full visibility at <a href="https://bit.ly/ysds-flotbio" target="_blank" rel="ugc noopener noreferrer">https://bit.ly/ysds-flotbio</a>.</p><p>---</p><p>⭐️ ABOUT THE SPEAKER</p><p><br></p><p>Fredrik joined Camurus in 2002 as a member of the board and CEO in 2003. Before this, he was CEO of Heptahelix AB and a leading academic at Lund University and the University of Oxford. </p><p>🔗 LINKS MENTIONED</p><ul><li>Camurus’ website - <a href="https://www.camurus.com/" target="_blank" rel="ugc noopener noreferrer">https://www.camurus.com/</a></li><li>Oczyesa’s approval - <a href="https://www.camurus.com/media/press-releases/2025/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu/" target="_blank" rel="ugc noopener noreferrer">https://www.camurus.com/media/press-releases/2025/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu/</a></li><li>Brixadi’s approval - <a href="https://braeburnrx.com/media/press-releases/braeburns-brixadi-buprenorphine-extended-release-subcutaneous-injection-ciii-receives-fda-approval-for-moderate-to-severe-opioid-use-disorder" target="_blank" rel="ugc noopener noreferrer">https://braeburnrx.com/media/press-releases/braeburns-brixadi-buprenorphine-extended-release-subcutaneous-injection-ciii-receives-fda-approval-for-moderate-to-severe-opioid-use-disorder</a></li><li>Empire of Pain: The Secret History of the Sackler Dynasty - <a href="https://www.amazon.com/Empire-Pain-History-Sackler-Dynasty/dp/0385545681" target="_blank" rel="ugc noopener noreferrer">https://www.amazon.com/Empire-Pain-History-Sackler-Dynasty/dp/0385545681</a></li><li>Camurus regains worldwide development and commercialization rights to CAM2029 from Novartis - <a href="https://www.camurus.com/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/" target="_blank" rel="ugc noopener noreferrer">https://www.camurus.com/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/</a></li><li>Camurus and Lilly enter collaboration and license agreement - <a href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" target="_blank" rel="ugc noopener noreferrer">https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/</a></li><li>Nitazenes: Super-strength opioids spreading across Europe and North America - UN - <a href="https://www.bbc.com/news/articles/crgge1ez0r2o" target="_blank" rel="ugc noopener noreferrer">https://www.bbc.com/news/articles/crgge1ez0r2o</a></li></ul><p><br></p><p>📜 TRANSCRIPT</p><p><br></p><p>Read the full transcript here: <a href="https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/" target="_blank" rel="ugc noopener noreferrer">https://flot.bio/episode/fredrik-tiberg-camurus-opioid-crisis/</a></p><p><br></p><p>📖 SHORT BLOGS BASED ON THIS EPISODE:</p><ul><li>Camurus CEO Fredrik Tiberg on Long-Acting Opioid Treatment: <a href="https://flot.bio/camurus-generic-drugs-opioid-use/" target="_blank" rel="noreferrer noop